文献速递妇科生殖医学

情绪不稳和抑郁限制子宫内膜异位症患者口服避孕药治疗

Mood lability and depression limit oral contraceptive therapy in endometriosis.
PubMed 文献 · Fertil Steril · 2024-12-12

该研究回顾性分析了2012至2024年间在大学附属医院治疗的2682名18至45岁子宫内膜异位症女性,评估口服避孕药引起的情绪不稳或抑郁对治疗维持的影响。结果显示44.2%的女性停用口服避孕药,其中33.9%因情绪不稳或抑郁停药,且52.7%的因情绪不稳停药者有抑郁诊断。联合口服避孕药与仅孕激素口服避孕药在因副作用停药方面无差异,孕激素类型也不影响因情绪不稳或抑郁停药。

要点

  • 子宫内膜异位症患者口服避孕药停药率达44.2%,其中33.9%因情绪不稳或抑郁停药。
  • 因情绪不稳停药者中52.7%有抑郁诊断,高于其他原因停药或未停药者。
  • 联合口服避孕药与仅孕激素口服避孕药因副作用停药无差异,孕激素类型不影响因情绪不稳停药。

核心结论

  • 子宫内膜异位症女性抑郁发生率增高,出现情绪不稳或抑郁时停用口服避孕药的可能性更大;口服避孕药对情绪不稳或抑郁的影响不因孕激素类型而异;对于有抑郁风险或服药后出现情绪变化的子宫内膜异位症患者,应考虑早期使用通常被视为二线的其他疗法。

研究设计与样本

  • 回顾性识别通过国际疾病分类第10版编码诊断为子宫内膜异位症的18至45岁女性,并进行全面电子病历审查,共纳入2012至2024年间在大学附属医院治疗的2682名患者。

主要发现

  • 总体44.2%的子宫内膜异位症女性停用口服避孕药。
  • 研究队列中抑郁患病率为33.6%。
  • 在停药者中,33.9%将停药归因于情绪不稳或抑郁。
  • 因情绪不稳停用口服避孕药者中52.7%有抑郁诊断,高于因其他原因停药或未停药者。
  • 联合口服避孕药与仅孕激素口服避孕药因副作用停药无差异;孕激素类型不影响因情绪不稳或抑郁停药。

临床怎么用

  • 对于有抑郁风险或服用口服避孕药后出现情绪变化的子宫内膜异位症患者,作者建议在治疗早期考虑通常被视为二线的其他疗法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the impact of oral contraceptive (OC)-induced mood lability/depression on treatment maintenance in women with endometriosis. DESIGN: Women with endometriosis were retrospectively identified through International Classification of Diseases, 10th Revision, codes, and then a comprehensive electronic medical record review was conducted, identifying mood lability/depression as a reason for treatment discontinuation with the use of combined or progestin-only OCs (POCs). SUBJECTS: A total of 2,682 women with endometriosis, between the ages of 18 and 45 years treated in a university-affiliated hospital between 2012 and 2024. EXPOSURE: Use of combined or POCs in patients with endometriosis. MAIN OUTCOME MEASURES: The primary outcome was OC discontinuation due to mood lability/depression in women with endometriosis. The secondary outcome assessed whether patients with a documented diagnosis of depression were more prone to discontinuing OC use due to mood lability. RESULTS: Mood lability/depression as a side effect of OC use was more common in women with endometriosis and increased the likelihood of discontinuing OCs. Overall, 44.2% of women with endometriosis and treated with OCs discontinued their use. The depression prevalence in our study cohort was 33.6%. Among those who discontinued, 33.9% attributed their discontinuation to mood lability/depression. Of those who discontinued OC use due to mood lability, 52.7% had a diagnosis of depression, a higher rate than those who discontinued OC use for other reasons or did not stop using OCs. There was no difference in OC discontinuation due to side effects comparing combination OCs with POCs. Similarly, the type of progestin prescribed did not influence the OC discontinuation among those who experienced mood lability/depression. CONCLUSION: Women with endometriosis had an increased incidence of depression and a greater likelihood of discontinuing OCs when they experienced mood lability or depression. Mood lability played a significant role in OC discontinuation. The effect of OC on mood lability/depression did not differ by the type of progestin. In patients with endometriosis at risk of depression or who develop mood changes on OCs, other therapies that are typically considered second line should be considered early in the course of treatment.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Cevik EC, Taylor HS. Mood lability and depression limit oral contraceptive therapy in endometriosis. Fertil Steril. 2024. PMID: 39672361. doi:10.1016/j.fertnstert.2024.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。